January 2005 in “世界胃肠病学杂志:英文版(电子版)” Etoposide makes radiation therapy more effective against tumors without major side effects.
October 1999 in “The Journal of Urology” New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
3 citations
,
August 2024 in “Frontiers in Oncology” Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
4 citations
,
July 2024 in “Radiotherapy and Oncology” A standardized scoring system is needed to improve model reliability for predicting hair loss in brain tumor patients treated with proton therapy.
September 2025 in “Value in Health”
4 citations
,
February 2024 in “The Journal of Urology” Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.
March 2003 in “Oncology Times” Further research is needed to develop effective cancer prevention strategies.
June 2026 in “Cancer Research Communications” The treatment combination is safe and effective for some patients with this type of breast cancer.
11 citations
,
May 2008 in “British journal of dermatology/British journal of dermatology, Supplement” Identical p53 gene mutations in different cancers suggest the need for careful treatment.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
October 2025 in “Plastic & Reconstructive Surgery” MNC-QQ cell therapy improved hair growth and quality of life in men with androgenic alopecia without adverse effects.
2 citations
,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
November 2018 in “Annals of oncology” A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.
400 citations
,
October 1995 in “Journal of clinical oncology” Docetaxel is effective against various cancers but mainly causes neutropenia.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
50 citations
,
June 1999 in “Annals of Oncology” Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
June 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” AQB reduces harmful skin changes in systemic sclerosis.
September 2010 in “European Urology Supplements” October 2021 in “European urology open science”
September 2020 in “Acta Scientific Cancer Biology” Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.